Loading...
•
Sep 30, 2023
Alnylam Q3 2023 Earnings Report
Alnylam reported strong commercial results and pipeline advancements, but was disappointed by the FDA's Complete Response Letter for ONPATTRO.
Key Takeaways
Alnylam Pharmaceuticals reported a 35% year-over-year increase in net product revenues, driven by the successful launch of AMVUTTRA. The company is on track to report topline results from the HELIOS-B Phase 3 study in early 2024 and reported positive topline results from the KARDIA-1 Phase 2 study of Zilebesiran.
Achieved global net product revenues of $313 million, representing 35% year-over-year growth.
Received Complete Response Letter from U.S. FDA for supplemental New Drug Application for Patisiran for the treatment of the Cardiomyopathy of ATTR Amyloidosis.
Company remains on track to report topline results from HELIOS-B Phase 3 study in early 2024.
Reported positive topline results from KARDIA-1 Phase 2 study of Zilebesiran.
Revenue by Segment
Forward Guidance
Alnylam updated its 2023 guidance for revenues from collaborations and royalties to $575 million to $625 million and reiterated its 2023 guidance for combined net product revenues of $1,200 million to $1,285 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...